KAT6A
KAT6A (Histone acetyltransferase KAT6A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Skin cancer, Breast cancer and 5 more.
Overview
Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2.
Open Targets scores its association with cancer at 0.67 (direct and indirect evidence; datatypes literature 0.98, animal model 0.48, genetic association 0.00, somatic mutation 0.86). IntOGen calls it a driver in 1 cohort (0 activating, 1 loss-of-function), covering Oesophageal Adenocarcinoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · KAT6A (Histone acetyltransferase KAT6A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Skin cancer, Breast cancer and 5 more.
- 1 · What it is
KAT6A (Histone acetyltransferase KAT6A) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Oesophageal cancer, Skin cancer, Breast cancer and 5 more.
- 2 · What goes wrong in cancer
Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity.
- 3 · How drugs use it
No product in this corpus aims at KAT6A yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:13013 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q92794 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000083168 (association with cancer (MONDO_0004992) 0.67; per-cancer scores at or above 0.5: colorectal cancer 0.53, ovarian cancer 0.52, melanoma 0.56, skin cancer 0.57, breast cancer 0.55, lung cancer 0.53 (GraphQL API, CC0)); IntOGen KAT6A (driver in 1 cohort (Act 0, LoF 1); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2. Acetylates p53/TP53 at 'Lys-120' and 'Lys-382' and controls its transcriptional activity via association with PML. May play a role in leukemogenic gene transcription. Location: Nucleus; Nucleus, nucleolus; Nucleus, nucleoplasm; Nucleus, PML body (UniProt). Locus 8p11.21 (HGNC).
- Oesophageal cancer: IntOGen driver in 1 cohort (ESCA)
- Skin cancer: Open Targets association 0.57 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.55 with breast cancer (MONDO_0007254)
- Colorectal cancer: Open Targets association 0.53 with colorectal cancer (MONDO_0005575)
- Lung cancer: Open Targets association 0.53 with lung cancer (MONDO_0008903)
- Ovarian cancer: Open Targets association 0.52 with ovarian cancer (MONDO_0008170)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it a loss-of-function (LoF) driver in 1 cohort; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"KAT6A" OR ABSTRACT:"KAT6A" OR TITLE:"lysine acetyltransferase 6A" OR ABSTRACT:"lysine acetyltransferase 6A" OR TITLE:"Histone acetyltransferase KAT6A" OR ABSTRACT:"Histone acetyltransferase KAT6A" OR TITLE:"ZNF220" OR ABSTRACT:"ZNF220" OR TITLE:"RUNXBP2" OR ABSTRACT:"RUNXBP2" OR TITLE:"MYST3" OR ABSTRACT:"MYST3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about KAT6A, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetNUTM1
Shares Oesophageal and junctional adenocarcinoma, Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetCDX2
Shares Oesophageal and junctional adenocarcinoma, Lung cancer (all types), Skin cancer (all types), Oesophageal cancer.
- TargetAFDN
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetATP2B3
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetAFF4
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetACVR1B
Shares Lung cancer (all types), Skin cancer (all types), Breast cancer (all types), IntOGen.
- TargetZBTB16
Shares Lung cancer (all types), Skin cancer (all types), Oesophageal cancer, Breast cancer (all types).
- TargetNBEA
Shares Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Breast cancer (all types), IntOGen.